ACRV Acrivon Therapeutics, Inc.: institutional ownership and insider trading
48 funds reported holding $39.9M of Acrivon Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $9.20M, with 6 new positions and 4 funds selling out; over the last 12 months insiders bought $115K and sold $40.4K on the open market.
Famous investors holding ACRV
- Renaissance Technologies (Renaissance Technologies): $1.35M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.14M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $73.5K, 0.0% of the portfolio
Largest institutional holders of ACRV
- RA CAPITAL MANAGEMENT, L.P. — $21.8M
- Sands Capital Alternatives, LLC — $4.07M
- ACADIAN ASSET MANAGEMENT LLC — $2.07M
- VANGUARD CAPITAL MANAGEMENT LLC — $1.69M
- VANGUARD GROUP INC — $1.68M
- WELLINGTON MANAGEMENT GROUP LLP — $1.58M
- RENAISSANCE TECHNOLOGIES LLC — $1.35M
- TWO SIGMA INVESTMENTS, LP — $1.14M
- MARSHALL WACE, LLP — $947K
- BRIDGEWAY CAPITAL MANAGEMENT, LLC — $674K
Recent ACRV insider trades
- Oct 5, 2026: Miller Mary sold 294 shares ($585)
- Aug 25, 2026: Blume-Jensen Peter sold 14,036 shares ($31.0K)
- Aug 18, 2026: Blume-Jensen Peter sold 1,713 shares ($3.44K)
- Aug 18, 2026: Devroe Eric sold 604 shares ($1.21K)
5%+ owners
- RA Capital Management, L.P.: 28.8% (Schedule 13D/A, filed Apr 23, 2026)
- Sands Capital Life Sciences Pulse Fund II, L.P.: 5.3% (Schedule 13G/A, filed Aug 13, 2026)